Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. Th...
Q1 2026
Dec 31, 2025
FY 2025
Sep 30, 2025
Q4 2025
Q3 2025
Jun 29, 2025
Q2 2025
Mar 31, 2025